465 related articles for article (PubMed ID: 21955849)
1. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Chun J; Brinkmann V
Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
Brinkmann V; Billich A; Baumruker T; Heining P; Schmouder R; Francis G; Aradhye S; Burtin P
Nat Rev Drug Discov; 2010 Nov; 9(11):883-97. PubMed ID: 21031003
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
4. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
7. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Gasperini C; Ruggieri S
Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
[TBL] [Abstract][Full Text] [Related]
8. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
9. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
10. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
11. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
12. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
13. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
14. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP
Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337
[TBL] [Abstract][Full Text] [Related]
15. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
16. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Chiba K; Yoshii N
Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):265-74. PubMed ID: 22728990
[No Abstract] [Full Text] [Related]
18. Fingolimod is a potential novel therapy for multiple sclerosis.
Aktas O; Küry P; Kieseier B; Hartung HP
Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
[TBL] [Abstract][Full Text] [Related]
19. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Kipp M; Amor S
Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
[TBL] [Abstract][Full Text] [Related]
20. ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
Hopkins CR
ACS Chem Neurosci; 2011 Mar; 2(3):116-7. PubMed ID: 22778861
[No Abstract] [Full Text] [Related]
[Next] [New Search]
